Imfinzi is now the only immunotherapy approved ... The recommended dose of durvalumab is 1,500mg every four weeks for subjects weighing 30kg or more and 20mg/kg for individuals under 30kg.

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the risk of bladder cancer progressing or returning to patients, according to a new study. Patients were given ...